Modified GRF 1-29 · CJC-1295 without DAC · CJC-1295 ohne DAC
Highest evidence
Human trial
Studies recorded
4· 4 in humans
Legal status · US
Research only
Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Tetrasubstituted synthetic analogue of GHRH(1-29), traded on the grey market as "CJC-1295 without DAC". Closely related to sermorelin (GHRH 1-29); a short-acting growth-hormone-releasing-hormone analogue often combined with a GHRP/ghrelin mimetic. Not approved as a medicinal product. Direct human trials of this exact analogue are essentially absent; the factual basis relies on related GHRH(1-29) analogues.
Researched for
GHRH receptor binding at the pituitary (mechanistic)Stimulation of endogenous GH release (related analogues)Body composition (theoretical / anecdotal)
Official status
US: Research only
Not approved by the FDA as a medicinal product. Marketed only as a research chemical on the grey market. GHRH analogues are on the WADA Prohibited List and banned in competitive sport.
Synthetic analogue of the first 29 amino acids of growth-hormone-releasing hormone (GHRH 1-29). Four amino-acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) are intended to slow degradation by dipeptidyl peptidase-IV and increase enzymatic stability relative to native GHRH. Like the native hormone and sermorelin, it binds the GHRH receptor on somatotroph cells of the anterior pituitary; mechanistically this is expected to stimulate endogenous growth-hormone release. Unlike the DAC-conjugated CJC-1295 variant, it lacks albumin binding, so its duration of action remains short.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
3 observations · 3 tiers
Human trial
1
Preclinical
1
Anecdotal
1
03
What the studies show
Human trial
Mensch, Studien zu nahe verwandten GHRH(1-29)-Analoga (GHRH 1-29 / Sermorelin)
Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R 1993
Binding to the GHRH receptor and triggering of growth-hormone release (class effect of GHRH(1-29) analogues)
What does NOT follow: The evidence comes from studies on native GHRH(1-29) and sermorelin, not from controlled trials of this exact tetrasubstituted analogue. The extrapolation is mechanistically plausible but not directly established.
Preclinical
Strukturchemisch / praeklinisch hergeleitet
Increased enzymatic stability and longer duration of action versus native GHRH(1-29) due to the four substitutions
What does NOT follow: Structure-based expectation; quantitative human pharmacokinetic data for this exact analogue are largely absent.
Anecdotal
Selbstberichte aus Fitness-Communities
Claimed changes in body composition when combined with GHRP/ghrelin mimetics
What does NOT follow: No controlled human studies of this analogue on body-composition endpoints; only unblinded self-reports without verification of substance identity.
04
Where studies disagree
Open question
Do the human data on GHRH(1-29)/sermorelin apply directly to the tetrasubstituted Mod GRF (1-29)?
POSITION A
Because the analogue uses the same GHRH(1-29) sequence base and the same receptor, a comparable GH-stimulating effect is mechanistically plausible.
POSITION B
The four substitutions alter stability and pharmacokinetics; without controlled trials of this exact analogue the extrapolation remains unproven, and grey-market products have unverified identity and purity.
CURRENT STATE · Direct human evidence on this exact analogue is essentially absent; only the activity of the related GHRH(1-29) substances is established.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 0.5 h. Pure pharmacokinetic model — not a dosing recommendation.
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
There is no approved human use for this substance. What circulates online about amounts and frequency is self-experimentation without a safety net.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
Mod GRF 1-29 is frequently equated with 'CJC-1295 without DAC' in forums and described as a short-acting GHRH pulse, usually combined with a GHRP.
common, often confusing name conflation
Not supported by studies: The naming confusion (CJC-1295 with vs. without DAC) regularly leads to false assumptions about duration of action. Robust human data on this specific compound are largely absent; expectations rest on GHRH biology, not on its own controlled studies.
11
Legal status by country
Country
Status
Note
Checked
United States
Research only
Not approved by the FDA as a medicinal product. Marketed only as a research chemical on the grey market. GHRH analogues are on the WADA Prohibited List and banned in competitive sport.
2026-06-07
Germany
Unapproved
Not approved as a medicinal product; AMG and HWG apply. Placing on the market and advertising for human use are legally problematic. GHRH analogues are on the WADA Prohibited List.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R · 1993
Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · 2006
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults